Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trialResearch in context

Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trialResearch in context

Summary: Background: Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, Limosilactobacillus reuteri (ILP100-Topical), has been demonstrated to accelerate wound healing in controlled...

Full description

Bibliographic Details
Main Authors: Emelie Öhnstedt, Evelina Vågesjö, Andreas Fasth, Hava Lofton Tomenius, Pia Dahg, Sofia Jönsson, Nisha Tyagi, Mikael Åström, Zhanar Myktybekova, Lovisa Ringstad, Margareth Jorvid, Peter Frank, Per Hedén, Stefan Roos, Mia Phillipson
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EClinicalMedicine
Subjects:
CXCL12
ILP100
Limosilactobacillus
Phase 1 clinical trial
Immunotherapy
SITUSAFE
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023001918

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023001918

Similar Items